{
  "clicked": false,
  "_replaced_more": false,
  "archived": false,
  "num_comments": 0,
  "created": 1444681537.0,
  "saved": false,
  "selftext": "This is an automatic summary, [original](http://www.reuters.com/article/2015/10/12/us-eli-lilly-study-idUSKCN0S61BV20151012) reduced by 59%.\n*****\n> The setback, announced by the company on Monday, also hit shares of Merck & Co Inc, which is now the only major drugmaker still moving aggressively ahead with a member of the novel family of drugs called CETP inhibitors.\n\n> Lilly&#039;s drug evacetrapib, like rival CETP inhibitors, is meant to sharply raise &quot;Good&quot; HDL cholesterol while cutting levels of &quot;Bad&quot; LDL cholesterol.\n\n> Current cholesterol fighters called statins, such as Pfizer Inc&#039;s Lipitor, prevent artery-clogging by slashing LDL levels, but have little impact on heart-protective HDL. Lilly said it stopped the evacetrapib study on the recommendation of an independent data-monitoring committee, which cited insufficient efficacy of the drug.\n\n> He now expects no sales from the drug, even though Lilly will continue to test it in smaller ongoing studies.\n\n> Analysts said Merck&#039;s drug is the only major remaining CETP inhibitor and remains a potential strong competitor to two recently approved cholesterol drugs called PCSK9 inhibitors that can slash LDL levels 60 percent beyond reductions seen with statins alone.\n\n> Indianapolis-based Lilly is conducting no other late-stage trials of cardiovascular drugs, one of its seven key areas.\n\n\n*****\n[**Summary Source**](http://smmry.com/http://www.reuters.com/article/2015/10/12/us-eli-lilly-study-idUSKCN0S61BV20151012) | [FAQ](http://www.reddit.com/r/autotldr/comments/31b9fm/faq_autotldr_bot/ \"Version 1.6, ~3542 summaries so far.\") | [Theory](http://www.reddit.com/r/autotldr/comments/31bfht/theory_autotldr_concept/) | [Feedback](http://www.reddit.com/message/compose?to=%23autotldr \"PMs and comment replies are read by the bot admin, constructive feedback is welcome.\") | *Top* *five* *keywords*: **Lilly**^#1 **drug**^#2 **inhibitor**^#3 **percent**^#4 **Merck**^#5\n\nPost found in [/r/news](http://np.reddit.com/r/news/comments/3ogh71/eli_lilly_halts_heart_drug_study_stock_tumbles_as/).\n\n*NOTICE*: This thread is for discussing the submission topic only. Do not discuss the concept of the [autotldr](http://www.reddit.com/user/autotldr) bot here.",
  "mod_reports": [],
  "secure_media_embed": {},
  "edited": false,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>This is an automatic summary, <a href=\"http://www.reuters.com/article/2015/10/12/us-eli-lilly-study-idUSKCN0S61BV20151012\">original</a> reduced by 59%.</p>\n\n<hr/>\n\n<blockquote>\n<p>The setback, announced by the company on Monday, also hit shares of Merck &amp; Co Inc, which is now the only major drugmaker still moving aggressively ahead with a member of the novel family of drugs called CETP inhibitors.</p>\n\n<p>Lilly&#039;s drug evacetrapib, like rival CETP inhibitors, is meant to sharply raise &quot;Good&quot; HDL cholesterol while cutting levels of &quot;Bad&quot; LDL cholesterol.</p>\n\n<p>Current cholesterol fighters called statins, such as Pfizer Inc&#039;s Lipitor, prevent artery-clogging by slashing LDL levels, but have little impact on heart-protective HDL. Lilly said it stopped the evacetrapib study on the recommendation of an independent data-monitoring committee, which cited insufficient efficacy of the drug.</p>\n\n<p>He now expects no sales from the drug, even though Lilly will continue to test it in smaller ongoing studies.</p>\n\n<p>Analysts said Merck&#039;s drug is the only major remaining CETP inhibitor and remains a potential strong competitor to two recently approved cholesterol drugs called PCSK9 inhibitors that can slash LDL levels 60 percent beyond reductions seen with statins alone.</p>\n\n<p>Indianapolis-based Lilly is conducting no other late-stage trials of cardiovascular drugs, one of its seven key areas.</p>\n</blockquote>\n\n<hr/>\n\n<p><a href=\"http://smmry.com/http://www.reuters.com/article/2015/10/12/us-eli-lilly-study-idUSKCN0S61BV20151012\"><strong>Summary Source</strong></a> | <a href=\"http://www.reddit.com/r/autotldr/comments/31b9fm/faq_autotldr_bot/\" title=\"Version 1.6, ~3542 summaries so far.\">FAQ</a> | <a href=\"http://www.reddit.com/r/autotldr/comments/31bfht/theory_autotldr_concept/\">Theory</a> | <a href=\"http://www.reddit.com/message/compose?to=%23autotldr\" title=\"PMs and comment replies are read by the bot admin, constructive feedback is welcome.\">Feedback</a> | <em>Top</em> <em>five</em> <em>keywords</em>: <strong>Lilly</strong><sup>#1</sup> <strong>drug</strong><sup>#2</sup> <strong>inhibitor</strong><sup>#3</sup> <strong>percent</strong><sup>#4</sup> <strong>Merck</strong><sup>#5</sup></p>\n\n<p>Post found in <a href=\"http://np.reddit.com/r/news/comments/3ogh71/eli_lilly_halts_heart_drug_study_stock_tumbles_as/\">/r/news</a>.</p>\n\n<p><em>NOTICE</em>: This thread is for discussing the submission topic only. Do not discuss the concept of the <a href=\"http://www.reddit.com/user/autotldr\">autotldr</a> bot here.</p>\n</div><!-- SC_ON -->",
  "downs": 0,
  "user_reports": [],
  "over_18": false,
  "score": 1,
  "stickied": false,
  "domain": "self.autotldr",
  "is_self": true,
  "hidden": false,
  "_orphaned": {},
  "_api_link": "https://api.reddit.com/r/autotldr/comments/3ohlzq/eli_lilly_halts_heart_drug_study_stock_tumbles_as/?ref=search_posts",
  "_comments_by_id": {},
  "visited": false,
  "thumbnail": "",
  "_has_fetched": true,
  "gilded": 0,
  "hide_score": false,
  "_info_url": "https://api.reddit.com/api/info/",
  "created_utc": 1444681537.0,
  "subreddit_id": "t5_2thsh",
  "id": "3ohlzq",
  "_params": {},
  "media_embed": {},
  "name": "t3_3ohlzq",
  "quarantine": false,
  "permalink": "https://www.reddit.com/r/autotldr/comments/3ohlzq/eli_lilly_halts_heart_drug_study_stock_tumbles_as/?ref=search_posts",
  "ups": 1,
  "url": "https://www.reddit.com/r/autotldr/comments/3ohlzq/eli_lilly_halts_heart_drug_study_stock_tumbles_as/",
  "title": "Eli Lilly halts heart drug study, stock tumbles as much as 9 percent"
}